Mr. Matt Chatterton reports

UNIDOC HEALTH AND VENTRIPOINT DIAGNOSTICS SIGN MOU TO EVALUATE SCALABLE REMOTE CARDIAC ASSESSMENT AND SCREENING PLATFORM

Ventripoint Diagnostics Ltd. has signed a memorandum of understanding (MOU) with UniDoc Health Corp. to evaluate a potential collaboration focused on remote cardiac assessment and cardiovascular screening.

The proposed collaboration is intended to assess how Ventripoint's VMS+ platform can become an integrated component of scalable remote cardiac assessment programs delivered through UniDoc's expanding connected-care infrastructure. The initiative could create new deployment opportunities for VMS+ while enabling advanced cardiac imaging to reach patients who currently have limited access to specialist cardiovascular services.

Under the proposed collaboration, UniDoc's configurable H 3 Health Cubes, virtual-care software and diagnostic-device integrations would be combined with Ventripoint's artificial-intelligence-enabled VMS+ cardiac imaging platform. The parties intend to evaluate a hub-and-spoke model in which community-based screening and echocardiographic image acquisition at spoke locations are connected with qualified cardiology hubs for review, interpretation, referral and follow-up.

The initiative aligns with Ventripoint's broader strategy of expanding access to advanced cardiac imaging through decentralized care models and is intended to help improve access to specialist cardiovascular assessment in remote, rural, indigenous and other underserved communities, where clinically appropriate and permitted by applicable regulatory requirements.

Proposed areas of collaboration

Ventripoint's VMS+ platform uses artificial intelligence and proprietary cardiac modeling technology to transform standard two-dimensional echocardiography images into three-dimensional cardiac models and quantitative measurements of the structure and function of all four chambers of the heart. Unlike conventional echocardiography workflows that often rely heavily on qualitative assessment, VMS+ is designed to provide accurate volumetric cardiac measurements comparable with cardiac MRI using standard ultrasound images, making advanced ventricular analysis more accessible in community and remote-care settings.

Under the MOU, the parties intend to assess the technical and operational feasibility of offering VMS+ as an optional cardiac imaging component within selected UniDoc Health Cube configurations and related virtual-care deployments.

Initial activities are expected to include:

• Identifying potential pilot locations, target populations, clinical purposes and referral pathways;
• Assessing equipment, training, installation, connectivity, interoperability, cybersecurity, privacy and data-flow requirements;
• Designing workflows that connect community-based image acquisition and virtual consultation with qualified cardiology specialists;
• Evaluating applications in cardiovascular screening, earlier disease detection, longitudinal disease management and specialist consultations;
• Identifying potential health care, government, indigenous, non-governmental, research, and funding partners for approved pilot or demonstration programs.

Executive commentary

"UniDoc's objective is to improve access to healthcare services through connected-care solutions and innovative technologies. We believe the opportunity to evaluate advanced cardiac assessment within our care-delivery ecosystem aligns with our broader vision of bringing specialized health care capabilities closer to patients, regardless of geography."

Antonio Baldassarre, chief executive officer, UniDoc Health

"Access to accurate and timely cardiac information can be especially challenging in remote and underserved communities. By combining VMS+ within UniDoc's connected-care infrastructure, we believe there is an opportunity to develop practical pathways that link local assessment with specialist expertise and support more informed care throughout a patient's journey."

Hugh MacNaught

President and chief executive officer, Ventripoint Diagnostics

Potential clinical applications may include pulmonary hypertension, heart failure, valvular dysfunction, congenital and childhood-onset heart disease, and other cardiovascular conditions for which advanced ventricular function analysis may provide meaningful clinical information.

Any pilot or commercial deployment would require a separate written project plan or definitive agreement addressing clinical governance, regulatory requirements, informed consent, privacy, cybersecurity, data residency, training, quality assurance, patient follow-up, costs, commercial terms and implementation responsibilities.

The MOU is non-exclusive and principally non-binding, other than certain customary provisions identified in the MOU. Neither party is obligated to purchase, sell, licence, integrate, or deploy any product or service. There can be no assurance that a definitive agreement will be entered into or that any pilot or commercial program will proceed.

About Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics is a leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ platform is powered by its proprietary knowledge-based reconstruction technology, developed over more than a decade and designed to provide accurate volumetric cardiac measurements equivalent to MRI for all four chambers of the heart.

VMS+ is compatible with leading ultrasound systems from major vendors and is designed for deployment across hospital, community and remote-care settings. The platform enables advanced cardiac imaging and longitudinal ventricular function analysis without requiring additional imaging hardware, supporting broader access to specialist-quality cardiac assessment.

We seek Safe Harbor.